Prabhu Kirti S, Kuttikrishnan Shilpa, Mariyam Zahwa, Habeeba Ummu, Panicker Anu Jayanthi, Masoodi Tariq, Junejo Kulsoom, Uddin Shahab
Translational Research Institute, Academic Health System, Hamad Medical Corporation, PO Box 3050, Doha, 3050, Qatar.
General Surgery Department, Hamad General Hospital, Hamad Medical Corporation, Doha, 3050, Qatar.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 17. doi: 10.1007/s00210-025-04297-3.
Cancer stem cells (CSCs) are a small subpopulation bearing self-renewal ability, mediating tumor initiation and propagation. Several molecular pathways, including the PI3K/AKT/mTOR pathway, are known to be aberrantly activated in cancers. In CSCs, PI3K/AKT/mTOR pathway has been associated with attribution of various properties to cancer cells including stemness characteristics, proliferation, migration, epithelial to mesenchymal transition, and autophagy. Thus, targeting PI3K/AKT/mTOR pathway with novel inhibitors might help to control the growth and proliferation of the breast CSC population. Though many studies have focused on PI3K/AKT/mTOR pathway in breast cancer, limited literature is available on the role of PI3K/AKT/mTOR pathway in breast CSCs. Here, in our present review, we have highlighted the role of the PI3K/AKT/mTOR signaling pathway in breast CSCs and its applications in therapeutic targeting.
癌症干细胞（CSCs）是具有自我更新能力的一小部分亚群，介导肿瘤的起始和增殖。已知包括PI3K/AKT/mTOR通路在内的几种分子途径在癌症中被异常激活。在癌症干细胞中，PI3K/AKT/mTOR通路与赋予癌细胞各种特性有关，包括干性特征、增殖、迁移、上皮-间质转化和自噬。因此，用新型抑制剂靶向PI3K/AKT/mTOR通路可能有助于控制乳腺癌症干细胞群体的生长和增殖。尽管许多研究都聚焦于乳腺癌中的PI3K/AKT/mTOR通路，但关于PI3K/AKT/mTOR通路在乳腺癌症干细胞中的作用的文献有限。在此，在我们当前的综述中，我们强调了PI3K/AKT/mTOR信号通路在乳腺癌症干细胞中的作用及其在治疗靶向中的应用。
